Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $92.57 Consensus Price Target from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $92.5714.

Several research firms have recently weighed in on TARS. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, Mizuho cut their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st.

Insiders Place Their Bets

In other news, CEO Bobak R. Azamian sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the transaction, the chief executive officer owned 847,991 shares in the company, valued at approximately $52,193,846.05. The trade was a 1.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 10,773 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $942,637.50. Following the transaction, the insider owned 2,547 shares of the company’s stock, valued at approximately $222,862.50. This represents a 80.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,531 shares of company stock worth $3,639,977 in the last quarter. 9.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in TARS. Rockefeller Capital Management L.P. increased its stake in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of Tarsus Pharmaceuticals by 11.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after buying an additional 392 shares during the last quarter. Strs Ohio boosted its position in shares of Tarsus Pharmaceuticals by 4.8% in the first quarter. Strs Ohio now owns 8,800 shares of the company’s stock valued at $617,000 after acquiring an additional 400 shares during the period. Finally, Swiss National Bank grew its holdings in shares of Tarsus Pharmaceuticals by 0.8% during the 1st quarter. Swiss National Bank now owns 62,933 shares of the company’s stock worth $4,415,000 after purchasing an additional 500 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $79.95 on Thursday. The stock’s 50-day moving average is $68.37 and its two-hundred day moving average is $66.65. The firm has a market cap of $3.51 billion, a price-to-earnings ratio of -73.35 and a beta of 0.54. Tarsus Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $91.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The business had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. Analysts predict that Tarsus Pharmaceuticals will post -2.4 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.